If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
The complaint further alleged that the injections caused a permanent loss of mobility and function from which she never recovered, describing the use of the drug as a form of "chemical restraint" and outside the standard of care. The case highlights concerns about the off-label use of antipsychotics in elderly dementia patients, a practice for which the drug carries a black box warning from the FDA due to an increased risk of death. Billy Driver, Jr. is a California prisoner who has been involuntarily administered the long-acting injectable antipsychotic Invega Sustenna (paliperidone palmitate) since at least 2019. He has filed multiple federal civil rights lawsuits alleging the forced medication causes severe side effects, including gynecomastia, borderline diabetes, heart palpitations, chest pain, and kidney pain. In one suit, Driver v. Naranjo (filed January 2024), Driver alleged that psychiatrist Dr. Naranjo at the Richard J. Donovan Correctional Facility (RJD) in San Diego had twice threatened to use physical force if Driver continued to refuse the injections. A judge dismissed Driver v. Naranjo in February 2025, noting that Driver's involuntary medication was authorized by active court orders issued through California's Keyhea process. Since 2020, Driver has undergone six Keyhea hearings, at each of which a court found that if unmedicated he would be a danger to others, that he lacked insight into his own need for medication, and that he could not manage his own treatment.
=== Hemorrhage and trauma === Synthetic platelets have the potential to aid trauma care by rapidly enhancing hemostasis, reducing blood loss, and improving survival outcomes in hemorrhagic injuries. SynthoPlate, a liposome-based synthetic platelet surrogate, has been designed to mimic both platelet adhesion and aggregation mechanisms through heteromultivalent surface modifications. Studies have demonstrated that SynthoPlate maintains stability after sterilization via filtration and E-beam irradiation and remains viable during long-term suspension storage. In a porcine arterial injury model, a single intravenous dose of SynthoPlate resulted in 100% survival during the first hour post-injury, compared to 0% in saline-treated controls. Unlike unmodified liposomes, SynthoPlate was shown to enhance hemostasis while stabilizing mean arterial pressure, reducing blood loss, and improving survival outcomes. These findings suggest that platelet-mimicking nanoparticles could serve as a viable transfusion alternative for hemorrhage management in pre-hospital and battlefield settings. Peptide-based nanoparticles (pNPs) have been studied for their potential in hemorrhage control by mimicking natural clot formation. In vitro experiments demonstrated that pNPs, when incubated with CD105 and red blood cells, formed stable artificial clots with fibrous networks similar to natural thrombi. These clots resisted enzymatic degradation, maintaining structural integrity unlike natural fibrin clots.
== Mode of action == When used as a food additive, ractopamine added to feed can be distributed by the blood to the muscle tissues, where it serves as a full agonist to murine (mouse or rat) TAAR1, a receptor protein (not necessarily in humans). It is also an agonist to beta-adrenergic receptors and a dopamine releasing agent. A cascade of events will then be initiated to increase protein synthesis, which results in increased muscle fiber size. Ractopamine is known to increase the rate of weight gain, improve feed efficiency, and increase carcass leanness in finishing swine. Its use in finishing swine yields about 3 kg (6.6 lb) of additional lean pork per animal, and improves feed efficiency by 10%. In cattle on 28 January 2004 Elanco Animal Health made Optaflexx commercially available in the US. Optaflexx is a "medicated feed additive that is labeled only for use in steers or market heifers (not breeding heifers or bulls) during the last 28–42 days on feed."
Sources: en.wikipedia.org
In clinical trials, elagolix produced dose-dependent decreases in gonadotropin, estradiol, and progesterone levels in women. Median levels of estradiol were partially suppressed to 42 pg/mL (follicular phase levels) with 150 mg once daily and were fully or near-fully suppressed to 12 pg/mL (postmenopausal levels) with 200 mg twice daily. In a 21-day study in premenopausal women, the effects of elagolix on FSH levels were found to be maximal at a dosage of 300 mg twice per day or above, whereas its effects on LH and estradiol levels were maximal at a dosage of 200 mg twice per day or above. Levels of progesterone were maintained at anovulatory levels (<2 ng/mL) across the 21-day study period at dosages of elagolix of 100 mg twice per day and above. A dosage of elagolix of 400 mg twice per day appears to produce no greater suppression in gonadotropin or estradiol levels than a dosage of 300 mg twice per day in premenopausal women. Suppression of gonadotropin and sex hormone levels with elagolix occurs rapidly, within hours, and upon discontinuation of elagolix, gonadotropin and sex hormone levels remain suppressed for at least 12 hours, but show recovery within 24 to 48 hours. As a consequence of its suppression of gonadotropin and sex hormone levels, elagolix inhibits ovulation in women. Over the course of three menstrual cycles, the ovulation rate with elagolix was 50% at 150 mg once daily and 32% at 200 mg twice daily.
=== Peripheral appetite signaling/gastric sensorimotor function === Mechanisms of weight loss from ESG remains an area of active study. There are at least two mechanisms of peripheral appetite signaling thought to be mediated by ESG: first, increased sense of fullness during a meal leading to meal termination, potentially a result of the intact gastric fundus that serves as a food reservoir and the restriction to gastric expansion (accommodation) during a meal; and second, from delayed emptying of the stomach, which promotes a prolonged sensation of fullness after a meal.
both patentable and otherwise, should be shared 'without fee or stipulation'", or, given the "[difference] between patenting for personal gain and patenting in the public interest" whether "a new process or discovery [should be patented] in the public interest" — the medical profession had a further concern. The term, "patented medicine" strongly suggested the unscientific, testimonial-promoted, "cure all" preparation of the charlatan, quack, or snake oil salesman, universally known as a patent medicine. In 1911, the "free use" of more than 90% of the 250 patents that had been issued by the Patent Office to government employees had been given over, by those patentees, to "the government and the people of the United States". Given that, if the invention was "of any value", and the employee had not patented it, "there is the chance at any time that somebody else may take out the patent and collect royalties from the public", patenting was "for the protection of the public rather than for the protection of the patentee" and, in doing so, also "prevent[ed] some more mercenary individual from collecting royalties". In 1907, Frederick Cottrell, a colleague of Robertson's at the University of California, patented his electrostatic precipitator, designed to produce cleaner industrial chimney emissions (FC.1), and offered the rights to the University. From their view that the university's Charter precluded any commercial activity, the Regents of the University of California declined Cottrell's offer.
Findlay received criticism in July 2026 after her senior staff and MLAs were allegedly directed to no longer use the term "First Nations", but instead to use terms like "Indian". Although "Indian" is generally regarded as an archaic and offensive term, Findlay allegedly argued that its appearance in legal and official documents such as the federal Indian Act justified its use. Findlay denied that such a directive was given. In response to the allegations, former Premier of British Columbia Christy Clark called Findlay "kooky" and said Findlay "cannot win an election." In August 2026, Ian Paton accusing Findlay of offering him a paid job with an MLA's salary if he resigned his seat for her. Similarly, Rosalyn Bird said that when she refused to resign to allow Findlay to run in her riding, she threw a "tantrum," writing "she yelled at me, told me I was being selfish, told me this was about a bigger picture, then she hung up. The conversation was less than a minute." On August 23, 2026 Reann Gasper announced that she would step down as MLA of Abbotsford-Mission and allow party leader Findlay to run for her seat in a by-election. Gasper was promptly hired as Findlay’s deputy chief of staff. Offering an inducement in return for a politician’s resignation is a criminal offence. In August and September 2026, ten Conservative MLAs resigned from the party, criticizing Findlay's leadership.
Sources: en.wikipedia.org
==== Key physiological parameters in pharmacokinetics include ==== Half-life (t½) – The time required for the drug's plasma concentration to reduce by half. Volume of distribution (VD) – A theoretical volume that relates the total amount of a drug in the body to its measured concentration in the blood (or plasma). Total Clearance (Cltot) – A theoretical pharmacokinetic parameter that statistically explains the efficiency with which a drug is irreversibly eliminated from the body, quantified as the volume of plasma cleared of the drug per unit of time, typically measured in L/h or mL/min. Area Under the Curve (AUC) – The definite integral of the plasma drug concentration versus time curve from time zero to infinity, which represents the total systemic exposure of the body to a drug overtime (AUC0−∞).
In the case of tyrocidine, ring closure has been shown to be highly favorable due to 4 H-bonds helping the decapeptide backbone to adopt a stable conformation (See figure 5). This intramolecular cyclization occurs in a head-to-tail fashion involving the N-terminus of the D-Phe1 and the C-terminus of the L-Leu10 (See figure 4).
=== Geriatrics === Most antidepressants, including SNRIs, are safe and effective in the geriatric population. The geriatric population is at greater risk for adverse effects relating to drug interaction as they are more likely to experience polypharmacy. Decisions are often based on co-morbid conditions, drug interactions, and patient tolerance. Due to differences in body composition and metabolism, starting doses are often half that of the recommended dose for younger adults. Studies show that these factors also put the geriatric population at increased risk of adverse effects when treated with SNRIs but not with SSRIs.
In 2017, the US Food and Drug Administration (FDA) approved pembrolizumab for any unresectable or metastatic solid tumor with certain genetic anomalies (mismatch repair deficiency or microsatellite instability). This was the first time the FDA approved a cancer drug based on tumor genetics rather than tissue type or tumor site; therefore, pembrolizumab is a so-called tissue-agnostic drug. In the European Union, pembrolizumab is indicated for:
=== Excitotoxicity in Stroke and Neurodegeneration === Excessive activation of AMPARs, particularly those lacking the GluA2 subunit, leads to increased calcium permeability, contributing to neuronal injury and death—a phenomenon known as excitotoxity. This mechanism in involved in acute events such as stroke and in chronic neurodegenerative diseases. For instance, in ALS, motor neurons exhibit elevated levels of calcium-permeable AMPARs, rendering them more susceptible to excitotoxic damage.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.